Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alternative hypothesis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    83 result(s) found for: Alternative hypothesis. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2006-001201-28 Sponsor Protocol Number: 2006-02-27UUS Start Date*: Information not available in EudraCT
    Sponsor Name:Department of Gynaecology, Helse Finnmark, Klinikk Hammerfest
    Full Title: Self-administered vaginal misoprostol at home for cervical ripening prior to outpatient hysteroscopy: a randomised placebo-controlled trial.
    Medical condition: Intrauterine pathology
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002823-86 Sponsor Protocol Number: ENCHANTED Start Date*: 2015-02-04
    Sponsor Name:The George Institute for Global Health Australia
    Full Title: Enhanced Control of Hypertension and Thrombolysis Stroke Study
    Medical condition: Acute ischaemic stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-003731-31 Sponsor Protocol Number: 2005 PK 02 Start Date*: 2005-03-09
    Sponsor Name:University Hospitals of Leiceter NHS Trust
    Full Title: Pharmacogenetics and metabolism of cyclophosphamide in paediatric non-Hodgkin’s Lymphoma
    Medical condition: non-Hodgkin's Lymphoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-002853-21 Sponsor Protocol Number: RGHT000405 Start Date*: 2007-09-03
    Sponsor Name:Belfast Health & Social Care Trust [...]
    1. Belfast Health & Social Care Trust
    2. South Eastern Health & Social Care Trust
    Full Title: A randomized controlled trial of tea tree oil (5%) body wash versus standard body wash to prevent colonization with methicillin-resistant Staphylococcus aureus (MRSA) in critically ill adults
    Medical condition: Colonization with methicillin-resistant Staphylococcus aureus (MRSA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005399-34 Sponsor Protocol Number: ML19913 Start Date*: 2006-02-28
    Sponsor Name:N.V. Roche S.A.
    Full Title: A randomised, open-label, multi-national study to investigate the impact of bone marker feedback (at 2 months) on adherence to once monthly Ibandronate treatment for post-menopausal osteoporosis (PMO)
    Medical condition: osteoporosis in postmenopausal women
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Completed) BE (Completed) AT (Completed) PT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-003197-26 Sponsor Protocol Number: IOM-120 Start Date*: 2008-05-29
    Sponsor Name:BRACCO IMAGING
    Full Title: Studio randomizzato di fase IV, doppio cieco, multicentrico, per il confronto di Iomeron 400 con Visipaque 320 nell'angiografia coronarica con Tomografia Computerizzata a doppio tubo (DS-CTA)
    Medical condition: CAD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011085 Ischaemic coronary artery disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022110-29 Sponsor Protocol Number: SG006 Start Date*: 2010-10-08
    Sponsor Name:Synairgen Research Limited
    Full Title: A randomised, double-blind, placebo-controlled Phase II study, comparing the efficacy and safety of inhaled SNG001 to placebo administered to COPD patients after the onset of a respiratory viral in...
    Medical condition: Prevention or attenuation of COPD symptoms caused by respiratory viruses
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-004899-13 Sponsor Protocol Number: 310882 Start Date*: 2008-01-16
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: A multi-center, open-label, randomized, controlled, parallel-group study to assess efficacy and safety of an extended flexible regimen of the combined oral contraceptive SH T00186D (0.02 mg ethinyl...
    Medical condition: women suffering from primary dysmenorrhea
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020121-41 Sponsor Protocol Number: 11728 Start Date*: 2011-01-17
    Sponsor Name:Bayer Health Care AG, D-51368 Leverkusen
    Full Title: An uncontrolled, open-label, phase II study in subjects with metastatic adenocarcinoma of the colon or rectum who are receiving first line chemotherapy with mFOLFOX6 (oxaliplatin/ folinic acid/5-fl...
    Medical condition: Metastatic adenocarcinoma of the colon or rectum (metastatic CRC)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001824-36 Sponsor Protocol Number: 201201 Start Date*: 2012-07-12
    Sponsor Name:Medical University of Vienna, Department of Medicine III, Division of Nephrology und Dialysis
    Full Title: ORAL SODIUM BICARBONATE SUPPLEMENTATION IN PATIENTS WITH CHRONIC METABOLIC ACIDOSIS AND CHRONIC KIDNEY DISEASE
    Medical condition: Patients classified to have chronic kidney disease of stage 3 and 4 and chronic metabolic acidosis (venous serum HCO3- of <21mml/L on 2 separate measurements at least 1 day apart) should be include...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10027433 - Metabolism and nutrition disorders 10066569 Chronic acidosis LLT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004341-17 Sponsor Protocol Number: PCYC-1123-CA Start Date*: 2014-10-16
    Sponsor Name:Pharmacyclics LLC
    Full Title: A Multicenter Open-Label Phase 1b/2 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse...
    Medical condition: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-007926-21 Sponsor Protocol Number: H8A-MC-LZAN(b) Start Date*: 2009-08-05
    Sponsor Name:Eli Lilly and Company
    Full Title: Effect of Passive Immunization on the Progression of Alzheimer’s Disease: LY2062430 versus Placebo
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004973-83 Sponsor Protocol Number: S154.3.021 Start Date*: 2007-05-02
    Sponsor Name:Solvay Pharmaceuticals. Inc.
    Full Title: A Randomized, Multicenter, Double-blind, Parallel Group Study To Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients.
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) CZ (Prematurely Ended) FI (Prematurely Ended) EE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004971-37 Sponsor Protocol Number: STRU-09-06 Start Date*: 2007-04-05
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas' NHS Foundation Trust
    Full Title: Adalimumab for psoriasis patients who are non-responders to etanercept: An open-label study
    Medical condition: psoriasis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018579-12 Sponsor Protocol Number: SPD503-316 Start Date*: 2011-01-26
    Sponsor Name:Shire Pharmaceutical Development Ltd
    Full Title: A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children...
    Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10068451 ADHD, combined type LLT
    14.1 10037175 - Psychiatric disorders 10068453 ADHD, predominantly inattentive type LLT
    14.1 10037175 - Psychiatric disorders 10068452 ADHD, predominantly hyperactive-impulsive type LLT
    14.1 10037175 - Psychiatric disorders 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Prematurely Ended) FR (Completed) ES (Completed) SE (Completed) IE (Completed) AT (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010917-61 Sponsor Protocol Number: NSDnr.17525 Start Date*: 2010-08-25
    Sponsor Name:Haukeland University hospital
    Full Title: Glucocorticoid Replacement in Addison's disease
    Medical condition: Autoimmune Addison's disease is a rare and chronic disease wich leads to primary adrenal failure. The conventional glucocorticoid replacement therapy in primary adrenal insufficiency (Addison’s dis...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001130 Addison's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020538-24 Sponsor Protocol Number: GASAS-1002X Start Date*: 2011-02-16
    Sponsor Name:GABA International AG
    Full Title: White spot lesion development in post-orthodontic patients following weekly application of a 1.25% fluoride gel compared to placebo over 6 months
    Medical condition: To monitor the white spot lesion development and dental status under weekly applied 1.25% fluoride gel compared to placebo in patients after orthodontic treatment with multibracket appliances
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002540-33 Sponsor Protocol Number: IFCT-1701 Start Date*: 2017-12-15
    Sponsor Name:IFCT
    Full Title: A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with PDL1-positive stage IV Non-Small C...
    Medical condition: PD-L1 positive stage IV Non Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2023-000156-38 Sponsor Protocol Number: 20230123SE Start Date*: 2023-05-04
    Sponsor Name:Semmelweis University, Department of Internal Medicine and Oncology
    Full Title: Value-based health economic comparative study of subcutaneous and intravenous trastuzumab-pertuzumab for HER-2 positive metastatic breast cancer based on patient reported outcomes.
    Medical condition: HER-2 positive advanced breast cancer, locally unresectable or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004252-20 Sponsor Protocol Number: VITRIS.at Start Date*: 2010-09-03
    Sponsor Name:Medizinische Universität Innsbruck - Univ.-Klinik für Anästhesie und Allgemeine Intensivmedizin
    Full Title: A Multicenter, Randomized, Controlled Trial Assessing Arginine Vasopressin vs. Saline Placebo in Refractory Traumatic Hemorrhagic Shock Patients (VITRIS.at-Study)
    Medical condition: The purpose of the trial is to assess effects of arginine vasopressin vs. saline placebo on hospital admission rate and hospital discharge rate in presumed traumatic hemorrhagic shock patients afte...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10044541 Traumatic shock LLT
    9.1 10044541 Traumatic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 21:15:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA